Moderna disclosed a $1.5 billion financing package as part of a strategic plan to scale seasonal vaccine manufacturing and redeploy revenue into oncology and rare disease programs, aiming to reach break‑even by 2028. The company outlined plans to invest in an expanded seasonal vaccine franchise while advancing mRNA‑based oncology candidates and other therapeutic modalities. The funding provides runway to support pipeline development and manufacturing commitments as Moderna balances commercial vaccines with its long‑term therapeutic R&D ambitions.